While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.
Artificial Intelligence (AI) has significant potential to change the healthcare industry, from the way patients receive treatments to the ways in which drugs are discovered and manufactured.
Cell and gene therapies are rapidly advancing to late-stage clinical trials and commercialization.
With limited numbers of producers supplying large-volume parenterals (LVPs) to the US market, shortages can result when natural disasters or manufacturing problems interrupt production operations.
Increasing complexity, evolving treatment strategies, advancing technologies, data security challenges and the growing focus on patient centricity are all impacting the way in which clinical trials are conducted.
Even though the FDA has extended the deadline for compliance with unit serialization requirements, UPM Pharmaceuticals serialized its first commercial product in May 2017, well ahead of time.
Although small and medium-sized pharma and biotech companies are driving the growth of the industry, they often don’t receive the attention and assistance that are essential to their success.
Members of the pharmaceutical industry have a responsibility to guarantee both the supply of high-quality medicines and the safety of their personnel.
The CRO market is condensing while experiencing rapid growth.
The industry’s accelerating development of biopharmaceuticals has put pressure on the supply chain to improve and modernize fill/finish operations.
Companies are seeking access to new technologies, looking to expand their pipelines and therapeutic expertise and reach both new patient populations and geographies.
Liquid-filled hard-shell capsules enable formulators to overcome issues with complex APIs, while also achieving improved efficacy and safety.
Revolutionary change is occurring in the pharmaceutical industry.
The ramifications of an adverse biological occurrence are higher in the pharmaceutical industry than in any other.
Following a reorganization and finalization of its new growth strategy, SPI is re-engaging in innovation.
The manufacture of biologic drug products, particularly those that require aseptic processing, is quite complex and requires specialized expertise.
Recently, advances in the design, form, function and operation of bioprocessing equipment has made it possible to close — or functionally close — biological active ingredient (API) manufacturing operations.
API sterilization is a unique capability, and particularly important for products formulated as suspensions.
Over the past seven years, Samsung BioLogics has constructed three state-of-the-art production facilities offering end-to-end integrated services to support the rapidly expanding clinical and commercial needs of customers.
As the pharmaceutical industry shifts its focus from blockbusters to targeted therapies, the demand for active pharmaceutical ingredient (API) manufacturing capabilities at the kilogram scale is increasing.
Microbial fermentation continues to be an important upstream bioprocess for the production of conventional and next-generation biologics
Biopharmaceutical companies are increasingly relying on contract service providers with specialized lyophilization expertise and equipment.
How mergers and acquistions have made an impact.
Planning for growth and flexibility at the operational level.